About Cocrystal Pharma Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.cocrystalpharma.com/
Frequently Asked Questions
What is the 52-week range for COCP?
The 52-week high is $2.0299 and the 52-week low is $0.76.
What is the P/E ratio for COCP?
The P/E ratio data is currently unavailable.
What is the dividend yield for COCP?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -207.47%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1655.45%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.13.
Analyst Recommendation Trends
Wall Street analyst consensus for COCP over the last few months:
Latest COCP News
A norovirus breakthrough?; another women’s healthtech haul
Yale researchers untangled norovirus RNA and Evvy just pulled in $40 million for precision medicine in women's health.
Cocrystal Pharma’s new CEO hopes to crack the norovirus code
James Sapirstein is bringing his Big Pharma chops to the clinical-stage company’s efforts to finally deliver an effective treatment for the vexing stomach bug.
Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment
No serious adverse events reported to date Preliminary efficacy results expected in late 2026 or early 2027 MIAMI, Fla. And BOTHELL, Wash., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced that the last subject has been dosed in its Phase 1b norovirus challenge study (NCT07198139) evaluating CDI-988
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-05 | FROST PHILLIP MD ET AL | +10,000 | $0.9816 | $9,816 |
| 2026-08-03 | FROST PHILLIP MD ET AL | +75,000 | $0.9412 | $70,590 |
| 2026-06-03 | SAPIRSTEIN JAMES | +235,000 | - | - |
| 2026-02-24 | FROST PHILLIP MD ET AL | +20,000 | $0.9976 | $19,952 |
| 2026-02-06 | FROST PHILLIP MD ET AL | +50,000 | $0.9456 | $47,280 |
| 2026-01-09 | Kornberg Roger D. | +24,615 | - | - |
| 2026-01-09 | Lee Sam | +49,229 | - | - |
| 2026-01-09 | Martin James Joseph | +49,229 | - | - |
| 2026-01-09 | FROST PHILLIP MD ET AL | +24,615 | - | - |
| 2026-01-09 | Japour Anthony J | +16,410 | - | - |
| 2026-01-09 | Rubin Steven D | +16,410 | - | - |
| 2026-01-09 | PFENNIGER RICHARD C JR | +16,410 | - | - |
| 2026-01-09 | Hassan Fred | +16,410 | - | - |
| 2025-12-31 | FROST PHILLIP MD ET AL | +50,000 | $0.9455 | $47,275 |
| 2025-12-30 | FROST PHILLIP MD ET AL | +20,000 | $0.9655 | $19,310 |
| 2025-12-26 | FROST PHILLIP MD ET AL | +40,000 | $0.9736 | $38,944 |
| 2025-12-24 | FROST PHILLIP MD ET AL | +25,000 | $0.9703 | $24,258 |
| 2025-11-26 | FROST PHILLIP MD ET AL | +2,500 | $0.99 | $2,475 |
| 2025-11-26 | FROST PHILLIP MD ET AL | +1,500 | $1 | $1,500 |
| 2025-11-25 | FROST PHILLIP MD ET AL | +20,000 | $0.9406 | $18,812 |
| 2025-10-28 | FROST PHILLIP MD ET AL | +719,426 | $1.39 | $1,000,002 |
| 2025-10-28 | FROST PHILLIP MD ET AL | +359,713 | $1.39 | $500,001 |
| 2025-10-28 | Martin James Joseph | +7,196 | $1.39 | $10,002 |
| 2025-10-28 | Martin James Joseph | +3,598 | $1.39 | $5,001 |
| 2025-10-28 | PFENNIGER RICHARD C JR | +40,000 | $1.39 | $55,600 |
| 2025-10-28 | PFENNIGER RICHARD C JR | +20,000 | - | - |
| 2025-10-28 | Hassan Fred | +719,426 | $1.39 | $1,000,002 |
| 2025-10-28 | Hassan Fred | +359,713 | $1.39 | $500,001 |